Fig. 6: CIK cell therapy plus IL-17A or anti-PD-1 treatment reversed the functions of exhausted CIK cells in vivo.
From: CD4+ T cells are required to improve the efficacy of CIK therapy in non-small cell lung cancer
A, B Subcutaneous growth of tumor cells (A549) in each group of NSG mice treated with CD4-CIK cells (n = 5), CD4-CIK cells+anti-PD-1 (n = 5), CD4-CIK cells+rIl-17 (n = 5), or CIK cells (n = 5). C Flow cytometric examination of the percentage of CD3+CD8+CD56+ T cells in CD3+CD8+ T cells. D Flow cytometric analysis of the percentage of PD-1+Tim-3+CD8+ T cells in CD3+CD8+ T cells. E Flow cytometric determination of the percentage of GzmB+IFN-γ+CD8+ T cells in CD3+CD8+ T cells. Error bars indicate SEM, *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 (one-way ANOVA or Student's t test).
